Download File - JOHN J. HADDAD, Ph.D.

More documents

Recommendations

Info

Index 215 Retropubic radical prostatectomy, for prostate cancer, 117 Reverse immunology approach, 12 Reverse transcription polymerase chain reaction (RT-PCR), 187. See also Polymerase chain reaction (PCR) RGS5. See Regulator of G-protein signaling 5 (RGS5) Rituxan, 75 RT-PCR. See Reverse transcription polymerase chain reaction (RT-PCR) SD-9427 (progenipoietin), agonist of, 121 Sequence-specific oligonucleotide probes (SSOPs), 190 Signal transduction pathways, 152, 165 Society for Biological Therapy, workshop for tetrameric technology, 194 Somatic cells, transfected, 134, 135 20 S proteasomes. See also Proteasomes heptameric rings of, 2 PA28 complex role in, 4 purification of, 12–13 types of, 2–4 Squamous intraepithelial lesions (SIL), 61 11 S regulator. See PA28 complex SSOPs. See Sequence-specific oligonucleotide probes (SSOPs) Staining, immunohistochemical, 187, 190, 191 STAT1, expression of, 3 Stimuvax, 75–76 Suppression subtractive hybridization, 111 Surrogate markers in cancer treatment, lack of, 79–80 TAA. See Tumor-associated antigens (TAA) TAP. See Transporters associated with antigen processing (TAP) TAP-negative tumor cells, 13 T cell receptor-like antibodies (TCRL Ab). See also TCR-like immunoglobulin (TCRL) detecting presence of peptide-HLA1 complexes, 185 T-cell repertoire, 155, 156, 158 T cells, 74. See also Cytolytic CD4 þ T cells; Cytolytic CD8 þ T cells activity of suppressor, 7, 45 antigen receptors, 110–111 antigen-specific, 138 antitumor, activity of, 7 antitumor responses, priming of, 7 CD4 þ , 111, 139, 140 CD8 þ , 141 in cell-mediated immunity, 84–86 CM, 163 CTL (See Cytotoxic T-lymphocyte (CTL)) cytolytic, response, 13 immune responses, 120–121 immune tolerance, 123 immunity of, 135 immunotherapy of, 182, 183 mediated identification of autologous tumor cells, 11–12 NK cells, 88 peripheral memory, 138, 140 prime-specific, 132 receptor expression, 4 regulatory, 121, 160 response induction, 18–20 self-reactive, 132 targets of autoreactive, 2 tumor antigen-specific, 158–160 tumor-specific, 33 types of, 1 T1 cells, responses, 144 T2 cells, TAP-deficient, 119 T-cell vaccines adjuvants in, 10–11 administration of, 10 aim of, 11–18 goal of, 2 MHC class II restricted peptides in, 9 minigene-based, 14–15 nucleic acid based, 16 optimal selection of, 7 proteasomes in, 2–4 protein-based, 15–16 effectiveness of, 19 selection of, 13–18 target antigens of, 11
216 Index TCRL. See TCR-like immunoglobulin (TCRL) TCRL Ab. See T cell receptor-like antibodies (TCRL Ab) TCR-like immunoglobulin (TCRL), 191–192 Terminal acetylation, C- and N-, 118 Tetanus helper peptide, 120 Tetramer, 193–194 assays, 120 monitoring of MKC1106-PP, 195 Tetramer assays, 120 TGF-b, 87 TGF-beta levels, 121 Theranostics, 181–183, 199 Thiol reductases, 8–9 Thymoproteasome catalytic subunits of, 2 expression of, 3 restricted expression in cTEC, 18 TIL. See Tumor-infiltrating lymphocytes (TIL) Time to progression (TTP), 75 TLR. See Toll-like receptors (TLR) TLR-9. See Toll-like receptors (TLR) TLR ligands, 156. See also Toll-like receptors (TLR) T lymphocytes. See also Cytotoxic T lymphocytes (CTL) CD4 þ , 111 hTRT-specific, 121 Toll-like receptors (TLR), 10, 140, 144 agonists, 63 TPP. See Time to progression (TTP) Traditional cancer vaccines, 69–70 versus therapeutic cancer vaccines, 78 Transfection, 133–134, 144 Transgene expression, 132–135. See also Plasmid vectors Translational approach, in drugs development, 169–175 Transmembrane trapping, 111 Transplantable rodent tumor cell lines, 31 use in preclinical immunotherapy studies, 32 Transporters associated with antigen processing (TAP), 1, 119, 120 Tregs. See T cells, activity of suppressor Tripeptidyl peptidase II (TPP II), 5–6 TRP-1. See Tyrosinase-related protein 1 (TRP-1) TRP2 360–368, antigenic peptide, 5 T2 tumors in cancer patients, 74 T3 tumors in cancer patients, 74 Tuberculosis, DNA vaccines for, 138 Tumor antigens, 110–111, 132, 192 binding to MHC1 molecule, 182, 191 regression of, 185 of T cells, 158–160 Tumor antigens, immunity to, 55 Tumor antigen-specific T cells, 158–160 Tumor-associated antigen MUC-1, 75 Tumor-associated antigens (TAA), 7, 16–18, 110–111, 182 assays of, 186–187 Tumor cells, 110, 111, 162. See also Peptide-pulsed targets antigens of, 158–160 cytokine-secreting, 37 larger, 160 micrometastases, 160 mixed with bcg, 37–38 as polyvalent vaccines, 57 profiling by flow cytometry, 58 regression in, 157, 158 Tumor-derived complexes, of HSP, 33 Tumorigenesis, 11, 12 Tumor immunology, principles of, 78 Tumor-infiltrating lymphocytes (TIL), 12, 93–94 Tumor lysate-pulsed DC, 89–91 intradermal vaccination of, 91–92 Tumor regression, 157, 158 Tumor sections, histopathology of, 56 Tumor-specific antigens, 70 Tumor-specific T cells, 33 Tyrosinase, 152, 171 in detecting MHC1 peptide complex, 192 peptides, 112, 120 Tyrosinase-related protein 1 (TRP-1), 139 Tyrosine kinase inhibitors. See Tyrosinase Ubiquitin (Ub) fusions, 14–15 UNC-93B, 10
Page 1 and 2:
Translational Medicine Series 6 Can
Page 3 and 4:
TRANSLATIONAL MEDICINE SERIES 1. Pr
Page 5 and 6:
Informa Healthcare USA, Inc. 52 Van
Page 8 and 9:
Preface Throughout the last 20 year
Page 10 and 11:
Preface vii Table 1 A Diverse Techn
Page 12 and 13:
Preface . . . . v Contributors . .
Page 14 and 15:
Contributors Pedro Alves Ludwig Ins
Page 16 and 17:
1 Factoring in Antigen Processing i
Page 18 and 19:
Factoring in Antigen Processing in
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
2 Outlining the Gap Between Preclin
Page 48 and 49:
Preclinical Models and Clinical Sit
Page 50 and 51:
Table 1 Examples of Preclinical Act
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68:
Page 71 and 72:
56 Srinivasan disease agents. Garda
Page 73 and 74:
58 Srinivasan expressing various kn
Page 75 and 76:
60 Srinivasan The above-mentioned a
Page 77 and 78:
62 Srinivasan (69). In another stud
Page 79 and 80:
64 Srinivasan patients with prostat
Page 81 and 82:
66 Srinivasan 33. Salgia R, Lynch T
Page 83 and 84:
68 Srinivasan 67. Werness BA, Levin
Page 85 and 86:
70 Teofilovici and Wentworth In 190
Page 87 and 88:
72 Teofilovici and Wentworth conduc
Page 89 and 90:
74 Teofilovici and Wentworth Lipono
Page 91 and 92:
76 Teofilovici and Wentworth (best
Page 93 and 94:
78 Teofilovici and Wentworth nature
Page 95 and 96:
80 Teofilovici and Wentworth In the
Page 97 and 98:
82 Teofilovici and Wentworth 17. Ba
Page 99 and 100:
84 Luptrawan et al. Dendritic cells
Page 101 and 102:
86 Luptrawan et al. of cancer cells
Page 103 and 104:
88 Luptrawan et al. NK cells can ki
Page 105 and 106:
90 Luptrawan et al. Figure 2 Repres
Page 107 and 108:
92 Luptrawan et al. state (50). Pat
Page 109 and 110:
94 Luptrawan et al. ability of TIL
Page 111 and 112:
96 Luptrawan et al. Figure 4 Drug s
Page 113 and 114:
98 Luptrawan et al. Figure 6 Tumor
Page 115 and 116:
Table 1 Summary of results of phase
Page 117 and 118:
102 Luptrawan et al. Table 1 Summar
Page 119 and 120:
104 Luptrawan et al. antigens (84,8
Page 121 and 122:
106 Luptrawan et al. 30. Ranges GE,
Page 123 and 124:
108 Luptrawan et al. 66. Dunn GP, B
Page 125 and 126:
110 Schroter and Minev proteins (2,
Page 127 and 128:
112 Schroter and Minev tumor-challe
Page 129 and 130:
114 Schroter and Minev Table 1 Inve
Page 131 and 132:
116 Schroter and Minev Table 1 Inve
Page 133 and 134:
118 Schroter and Minev demonstrated
Page 135 and 136:
120 Schroter and Minev loaded MART-
Page 137 and 138:
122 Schroter and Minev illustrate t
Page 139 and 140:
124 Schroter and Minev 4. Heemels M
Page 141 and 142:
126 Schroter and Minev 42. Minev BR
Page 143 and 144:
128 Schroter and Minev 74. Restifo
Page 146 and 147:
7 Multimodality Immunization Approa
Page 148 and 149:
Multimodality Immunization Approach
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Figure 5.1 Immunohistochemical char
Page 164 and 165:
Figure 8.5 A schematic representati
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
8 Bidirectional Bedside Lab Bench P
Page 172 and 173:
Development of Novel Immunotherapeu
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185: Development of Novel Immunotherapeu
Page 200 and 201: 9 Diagnostic Approaches for Selecti
Page 202 and 203: Diagnostic Approaches to Maximize T
Page 222: Diagnostic Approaches to Maximize T
Page 225 and 226: 206 Index Antigenic peptides degrad
Page 227 and 228: 208 Index Chromogens, enzymatic act
Page 229 and 230: 210 Index Freund’s adjuvants. See
Page 231 and 232: 212 Index Langerhans cells, 133, 13
Page 233: 214 Index [Peptide vaccines] invest
Page 238: Oncology and Immunology about the b
show all

Download File - JOHN J. HADDAD, Ph.D.

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?